AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02447432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)
Description: 4 doses by intramuscular injection in the right left anterolateral thigh
Study NCT02447432 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)
Description: 4 doses by intramuscular injection in the right anterolateral thigh
Study NCT02447432 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPw-HBV/Hib
Description: 3 doses by intramuscular injection in the left anterolateral thigh
Study NCT02447432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib
Description: 3 doses by intramuscular injection in the left anterolateral thigh
Study NCT00755898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of a 200 mg dose of amantadine hydrochloride
Description: Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
Study NCT00755898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of a 200 mg dose of amantadine hydrochloride
Description: Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
Study NCT00677092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
Study NCT02780102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-Motor Rehabilitation
Description: Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises
Study NCT02780102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin
Description: 2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.
Study NCT02780102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
Study NCT03945162 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ruvidar® (TLD-1433) Bladder infusion and PDT
Description: Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
Study NCT01795729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Coronary revascularization
Study NCT01795729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimal medical therapy
Description: Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
Study NCT01795729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal medical therapy
Description: Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
Study NCT02353455 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
Study NCT01836198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Study NCT01836198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Study NCT01836198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Study NCT01836198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study NCT00678977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
Study NCT00678977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
Study NCT00678977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
Study NCT05082623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music medicine
Study NCT05082623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Earplug
Description: Earplug with noise cancelling
Study NCT01667172 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Point-of-Care C Reactive Protein measurement on capillary blood
Description: capillary blood fingerstick method to determine C Reactive Protein level in the blood
Study NCT04300153 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESP Block
Description: At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
Study NCT04300153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block
Description: At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
Study NCT04300153 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Global Quality of Recovery-15 score
Description: Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.
Study NCT04300153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Quality of Recovery-15 score
Description: Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.
Study NCT04300153 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
Study NCT04300153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
Study NCT03715387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Topical 0.1% Topical Ointment
Description: Topical tacrolimus ointment
Study NCT03715387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polysporin Ointment
Description: Polysporin ointment
Study NCT04205487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
Study NCT04205487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
Study NCT05490823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A smartphone app for anemia screening
Description: This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
Study NCT00741585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any antihypertensive medication alone or in combination
Description: All drugs on awakening
Study NCT00741585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any antihypertensive medication alone or in combination
Description: One or more drugs at bedtime
Study NCT00741585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
Study NCT03252197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UGIJVC with needle guide device
Description: Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.
Study NCT03252197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UGIJVC without needle guide device
Description: participants who are tested performance for ultrasound guided cannulation using conventional method.
Study NCT02897180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nyaditum resae(R)
Description: Capsules containing Nyaditum resae(R)
Study NCT02897180 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containin Placebo
Study NCT04554342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V01 candy
Description: candy with sweetener (Isomalt) and apple flavour
Study NCT04554342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V02 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)
Study NCT04554342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V03 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
Study NCT04554342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V04 candy
Description: candy with sweetener (Isomalt) (control group 1)
Study NCT04554342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V05 candy
Description: candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
Study NCT04467710 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic common bile duct exploration.
Description: Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time.
Study NCT03232164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET
Description: 18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
Study NCT03414905 — intervention group
Intervention type: DEVICE
Intervention: Aspira Catheter
Description: * 15.5Fr catheter~* Standard of care
Study NCT01903369 — intervention group
Intervention type: DEVICE
Intervention: Shear Wave Elastography
Description: Shear wave elastography
Study NCT03414905 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Standard of care
Study NCT00431067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study NCT01762449 — intervention group
Intervention type: OTHER
Intervention: Followup survey
Study NCT02102100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
Study NCT02102100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menthol
Description: In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
Study NCT02798354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative
Description: 1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
Study NCT03626324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2P
Description: The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
Study NCT03545646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with High Intensity Focused ElectroMagnetic system
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
Study NCT04128891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Cardiomagnetic Resonance Imaging
Study NCT04128891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril-Valsartan
Description: Cardiomagnetic Resonance Imaging
Study NCT01860144 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Study NCT01835028 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Observational Study using Imaging and Biomarkers
Study NCT01835028 — intervention group
Intervention type: OTHER
Intervention: Computed tomography
Description: Observational Study using Imaging and Biomarkers
Study NCT01835028 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: Observational Study using Imaging and Biomarkers
Study NCT01835028 — intervention group
Intervention type: OTHER
Intervention: Blood biomarkers
Description: Observational Study using Imaging and Biomarkers
Study NCT01835028 — intervention group
Intervention type: OTHER
Intervention: Stress echocardiography
Description: Observational Study using Imaging and Biomarkers
Study NCT00306787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 500 mg tablet
Study NCT00306787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Valacyclovir 500 mg capsule
Study NCT00306787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching famciclovir
Description: Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
Study NCT00306787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching valacyclovir
Description: Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
Study NCT04616001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Patients will receive IVIG daily for four days.
Study NCT04415021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques
Description: Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
Study NCT04415021 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham Myofascial Release Techniques
Description: Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
Study NCT03623659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser assisted hatching
Description: After warming, blastocysts are subjected to laser assisted hatching (LAH) following the standard procedure.The LAH procedure lasts one minute per blastocyst.
Study NCT02436902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed one month after resection.
Study NCT02436902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is submitted one month after resection.
Study NCT02436902 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TACE plus sorafenib
Description: TACE plus sorafenib will be submitted one month after resection.
Study NCT02436902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: empty control
Description: This group will not receive adjuvant therapy.
Study NCT02436902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: empty control
Description: This group will not receive adjuvant therapy.
Study NCT02650622 — intervention group
Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
Study NCT01540084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
Study NCT01540084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
Study NCT02106143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RejuvenAir™ Radial Spray Cryotherapy
Description: Metered dose radial spray cryotherapy treatment
Study NCT03267602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: If following patients are suffering from sleep apnea and agree to receive treatment,~1. older than 18 years, AHI> 15 and present obvious symptoms or~2. less than 18 years, AHI still> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months.
Study NCT01082393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical tacrolimus treatment
Description: 4 applications (day 1,day 3, day 6 and day10)